Otilonium-d4 (bromide)

• UNSPSC Description:

  Otilonium-d4 (bromide) is deuterium labeled Otilonium (bromide).

• Target Antigen:

  Isotope-Labeled Compounds; mAChR

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling;Others

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(OC([2H])([2H])C([2H])([2H])[N+](CC)(CC)C)C1=CC=C(NC(C2=CC=CC=C2OCCCCCCCC)=O)C=C1.[Br-]

• Molecular Weight:

  567.59

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Battaglia, G., et al., Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther, 1998. 12(10): p. 1003-10.|[3]Clave, P., et al., Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther, 2011. 34(4): p. 432-42.|[4]Gandia, L., et al., Otilonium: a potent blocker of neuronal nicotinic ACh receptors in bovine chromaffin cells. Br J Pharmacol, 1996. 117(3): p. 463-470.|[5]Lindqvist, S., et al., The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts. Br J Pharmacol, 2002. 137(7): p. 1134-42.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported